MED12 and Miyoshi myopathy: Altogether, our data suggest that oncogenic cell growth in Mediator kinase-inhibited MM SCs appears to involve, at least in part, SE reprogramming leading to activation of pathways that recapitulate many of those found in patient-derived MED12-mutant tumors.